share_log

康哲藥業:截至二零二四年一月三十一日止月份之股份發行人的證券變動月報表

CMS: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024

香港交易所 ·  Feb 1 04:25
Summary by Moomoo AI
康哲藥業控股有限公司於2024年1月31日向香港交易及結算所有限公司提交了最新的證券變動月報表。報告顯示,公司的法定/註冊股本在本月內無變動,上月底及本月底結存均為20,000,000,000股,每股面值0.005美元,法定/註冊股本總額維持在100,000,000美元。此外,已發行股份在本月內亦無變動。公司確認,所有在本月發行的證券均已獲得董事會正式授權批准,並已履行所有相關法律及上市規則要求。報告由公司秘書吳三燕於2024年2月1日呈交。
康哲藥業控股有限公司於2024年1月31日向香港交易及結算所有限公司提交了最新的證券變動月報表。報告顯示,公司的法定/註冊股本在本月內無變動,上月底及本月底結存均為20,000,000,000股,每股面值0.005美元,法定/註冊股本總額維持在100,000,000美元。此外,已發行股份在本月內亦無變動。公司確認,所有在本月發行的證券均已獲得董事會正式授權批准,並已履行所有相關法律及上市規則要求。報告由公司秘書吳三燕於2024年2月1日呈交。
CONGE PHARMACEUTICAL HOLDINGS LIMITED FILED ITS LATEST MONTHLY SECURITIES FLUCTUATION REPORT WITH HONG KONG TRADING AND SETTLEMENT HOLDINGS LIMITED ON 31 JANUARY 2024. The report shows that the company's regulated/registered share capital remained unchanged during the month, with 20,000,000,000 shares outstanding at the end of last month and the end of this month, with a face value of $0.005 per share, and the total regulated/registered share capital remained at $100,000,000. In addition, the issued shares were unchanged during the month. The Company confirms that all securities issued this month have been formally authorized by the Board of Directors and have complied with all relevant legal and listing rules requirements. The report was submitted by the Company Secretary Wu Sanyan on 1 February 2024.
CONGE PHARMACEUTICAL HOLDINGS LIMITED FILED ITS LATEST MONTHLY SECURITIES FLUCTUATION REPORT WITH HONG KONG TRADING AND SETTLEMENT HOLDINGS LIMITED ON 31 JANUARY 2024. The report shows that the company's regulated/registered share capital remained unchanged during the month, with 20,000,000,000 shares outstanding at the end of last month and the end of this month, with a face value of $0.005 per share, and the total regulated/registered share capital remained at $100,000,000. In addition, the issued shares were unchanged during the month. The Company confirms that all securities issued this month have been formally authorized by the Board of Directors and have complied with all relevant legal and listing rules requirements. The report was submitted by the Company Secretary Wu Sanyan on 1 February 2024.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more